Cartesian Therapeutics (Cartesian Therapeutics) Debt-to-Equity : -0.03 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Debt-to-Equity?

Cartesian Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.17 Mil. Cartesian Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.79 Mil. Cartesian Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-440.18 Mil. Cartesian Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cartesian Therapeutics's Debt-to-Equity or its related term are showing as below:

RNAC' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.95 Med: 0.1 Max: 2.3
Current: -0.03

During the past 10 years, the highest Debt-to-Equity Ratio of Cartesian Therapeutics was 2.30. The lowest was -3.95. And the median was 0.10.

RNAC's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs RNAC: -0.03

Cartesian Therapeutics Debt-to-Equity Historical Data

The historical data trend for Cartesian Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Debt-to-Equity Chart

Cartesian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

2.30

-1.96

1.57

0.40

-0.03

Cartesian Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.40	0.51	0.53	0.17	-0.03

Competitive Comparison of Cartesian Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Cartesian Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cartesian Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Debt-to-Equity falls into.

Cartesian Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cartesian Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.166	+	8.789)	/	-440.184
	=	-0.02

Cartesian Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.166	+	8.789)	/	-440.184
	=	-0.02

Cartesian Therapeutics (NAS:RNAC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cartesian Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

1S7:Germany

Address

65 Grove Street, Watertown, MA, USA, 02472

Website

https://www.selectabio.com

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Executives

Carsten Brunn	director, officer: President & CEO	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber	officer: Chief Medical Officer	430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto	officer: Chief Scientific Officer	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston	officer: COO and SVP, R&D	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer	director	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan	officer: Chief Financial Officer	20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva	director	11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue	officer: VP Finance	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando	director
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan	officer: General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065